Avadel Pharma (NASDAQ: AVDL) reported Q4 EPS of ($0.05), $0.03 worse than the analyst estimate of ($0.02). Revenue for the quarter came in at $50.41 million versus the consensus estimate of $52.48 million.

GUIDANCE:

Avadel Pharma sees FY2025 revenue of $240-260 million, versus the consensus of $250.3 million.

For earnings history and earnings-related data on Avadel Pharma (AVDL) click here.